1Bando K, Yamada Y. Glimepiride(Amaryl): a review of its pharmacological and clinical profile.Nippon Yakurrigaku Zasshi. 2001, 118(1): 59.
2Bo Isomaa Peter Almgren, Tiinamaija Tumoi , et ,al Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes Care,2001,24:683.
3Alberfi KGMM, Zimmet PZ for the WHO Consultation Definition,and classification of diabetes mellitus and its complications. Part 1 : Diagnosis and classification of diabetes mellitus,provisional reprot of a WHO consultation. Diabet Med, 1998, 15:539.
4Groop L, Orho--Melander M. The dysmetabolic syndrome[J]. J Intern Med, 2001,250(1 ) : 105--.
5Pinkney JH, Stehouwer CD, Coppack SW,et al. Endothelial dysfunction: cause of the insulin resistance syndrome[J]. Diabetes.1997,46(Suppl 2) :S9--S12.
61999 Word Health Organization--International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee[J]. J Hypertens, 1999,17(2):151-183.
7Word Health Organization: Definition, diagnosis and classification of diabetes mellitus and classification of diabetes mellitus [S].Geneva. World Health Organization, 1999.
8Celermajer DS. Endothelial dysfunction: Does it matter?. Is it reversible[J]? J Am Cardiol, 1997,30(3),325-333.
9Creger MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans[J]. J Clin Invest, 1990,86(2):228-234.
10Ledoux M, Lambert J, Reeder BA, et al. Correlation between cardiovascular disease risk factors and simple anthropometric mea-sure. Canadian Heart Surveys Research Group[J]. CMAJ. 1997,157(Suppl i) :S46--S53.
